Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Status:
Terminated
Trial end date:
2022-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the feasibility and toxicity of administering
intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM)
malignancies.